Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases

References

• World Health ORganization. [cited 2023 Feb 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
   Google Scholar
• Lee DS, Wang CX, McAlister FA, et al. Factors associated with SARS-CoV-2 test positivity in long-term care homes: a population-based cohort analysis using machine learning. Lancet Reg Health Am. 2022;6:100146. doi: 10.1016/j.lana.2021.100146
   PubMedGoogle Scholar
• Ko Y, Ngai ZN, Koh RY, et al. Association among lifestyle and risk factors with SARS-CoV-2 infection. Tuberc Respir Dis (Seoul). 2023;86(2):102–110. doi: 10.4046/trd.2022.0125
   PubMed Web of Science ®Google Scholar
• Rosero PA, Realpe JS, Farinango CD, et al. Risk factors for COVID-19: a systematic mapping study. Stud Health Technol Inform. 2022;299:63–74.
   PubMedGoogle Scholar
• Oliver SE, Gargano JW, Marin M, et al. The advisory committee on immunization practices’ interim recommendation for use of pfizer-BioNTech COVID-19 vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922–1924. doi: 10.15585/mmwr.mm6950e2
   PubMed Web of Science ®Google Scholar
• Oliver SE, Gargano JW, Marin M, et al. The advisory committee on immunization practices’ interim recommendation for use of moderna COVID-19 vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653–1656. doi: 10.15585/mmwr.mm695152e1
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen IT, Chao CM, et al. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines. 2021;20(8):1013–1025. doi: 10.1080/14760584.2021.1949293
   PubMed Web of Science ®Google Scholar
• Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53(3):404–412. doi: 10.1016/j.jmii.2020.02.012
   PubMedGoogle Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818. doi: 10.1001/jamacardio.2020.1017
   PubMed Web of Science ®Google Scholar
• Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying Medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open. 2021;4(6):e2111182. doi: 10.1001/jamanetworkopen.2021.11182
   PubMed Web of Science ®Google Scholar
• Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003–e17. doi: 10.1016/S2214-109X(20)30264-3
   PubMed Web of Science ®Google Scholar
• Drozd M, Pujades-Rodriguez M, Lillie PJ, et al. Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK biobank observational cohort study. Lancet Infect Dis. 2021;21(8):1184–1191. doi: 10.1016/S1473-3099(20)30978-6
   PubMed Web of Science ®Google Scholar
• Soegiarto G, Purnomosari D, Wulandari L, et al. Incidence of SARS-CoV-2 infection in hospital workers before and after vaccination programme in East Java, Indonesia-A retrospective cohort study. Lancet Reg Health Southeast Asia. 2023;10:100130. doi: 10.1016/j.lansea.2022.100130
   PubMedGoogle Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi: 10.1056/NEJMoa2116044
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Lai CC, Wang YH, Chen KH, et al. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic Review and network meta-analysis of randomized controlled trials. Viruses. 2022;14(8):14. doi: 10.3390/v14081706
   Web of Science ®Google Scholar
• National Institute of Health. [cited 2023 Feb 25]. Available from: https://www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2022 Sep;5:ciac724. doi: 10.1093/cid/ciac724
   Google Scholar
• Hsu WH, Tsai YW, Wu JY, et al. Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors. J Infect. 2023;86(4):e107–e110. doi: 10.1016/j.jinf.2023.02.007
   PubMed Web of Science ®Google Scholar
• Liu TH, Wu JY, Huang PY, et al. The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: a retrospective cohort study including 91,528 patients. J Infect. 2023;86(3):256–308. doi: 10.1016/j.jinf.2023.01.014
   Web of Science ®Google Scholar
• Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416–427. doi: 10.1016/S2215-0366(21)00084-5
   PubMed Web of Science ®Google Scholar
• Wang W, Wang CY, Wang SI, et al. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619. doi: 10.1016/j.eclinm.2022.101619
   PubMedGoogle Scholar
• Liu T-H, Wu J-Y, Huang P-Y, et al. The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: a retrospective cohort study including 91,528 patients. J Infect. 2023;86(3):256–308. doi: 10.1016/j.jinf.2023.01.014
   Web of Science ®Google Scholar
• Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637–1638. doi: 10.1001/jama.2015.13480
   PubMed Web of Science ®Google Scholar
• Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342–e9. doi: 10.1093/cid/ciac443
   PubMed Web of Science ®Google Scholar
• Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538. doi: 10.1007/s00392-020-01626-9
   PubMed Web of Science ®Google Scholar
• Aggarwal G, Cheruiyot I, Aggarwal S, et al. Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: a meta-analysis. Curr Probl Cardiol. 2020;45(8):100617. doi: 10.1016/j.cpcardiol.2020.100617
   PubMed Web of Science ®Google Scholar
• Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with covid-19. Clin Infect Dis. 2022 Feb 18;76(4):563–572.
   Web of Science ®Google Scholar
• Rubin R. From positive to negative to positive again—the mystery of why COVID-19 rebounds in some patients who take paxlovid. JAMA. 2022;327(24):2380–2382. doi: 10.1001/jama.2022.9925
   PubMed Web of Science ®Google Scholar
• Lai CC, Hsueh PR. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment. J med virol. 2023;95(2):e28430. doi: 10.1002/jmv.28430
   PubMed Web of Science ®Google Scholar
• Wang L, Berger NA, Davis PB, et al. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv. 2022;22:2022. doi: 10.1101/2022.06.21.22276724
   Google Scholar
• Marsousi N, Daali Y, Fontana P, et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin Pharmacokinet. 2018;57(10):1347–1354. doi: 10.1007/s40262-018-0637-6
   PubMed Web of Science ®Google Scholar
• S K S, P A A, B S, et al. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: a evidence-based review from six databases. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2022;16(3):102451. doi: 10.1016/j.dsx.2022.102451
   PubMed Web of Science ®Google Scholar
• Marzolini C, Kuritzkes DR, Marra F, et al. Recommendations for the management of drug–drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (paxlovid) and comedications. Clin Pharmacol Ther. 2022;112(6):1191–1200. doi: 10.1002/cpt.2646
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Mengato D, Sasset L, et al. Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study. Viruses. 2023;15(2):15. doi: 10.3390/v15020384
   Web of Science ®Google Scholar